- Home
- INDB vs DNLI Comparison
INDB vs DNLI Comparison
Compare INDB & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INDB | DNLI |
|---|---|---|
| Founded | 1907 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | INDB | DNLI |
|---|---|---|
| Price | $85.19 | $25.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $87.00 | $34.33 |
| AVG Volume (30 Days) | 336.2K | ★ 1.7M |
| Earning Date | 04-16-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.32% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.83 | N/A |
| Revenue Next Year | $5.85 | $408.85 |
| P/E Ratio | $52.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $61.19 | $12.58 |
| 52 Week High | $87.00 | $25.97 |
Technical Indicators
Market Signals| Indicator | INDB | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 64.78 | 73.00 |
| Support Level | $76.40 | $18.27 |
| Resistance Level | $87.00 | N/A |
| Average True Range (ATR) | 1.53 | 1.24 |
| MACD | 0.33 | 0.35 |
| Stochastic Oscillator | 80.30 | 82.36 |
Price Performance
Historical ComparisonAbout INDB Independent Bank Corp.
Independent Bank Corp is a bank holding company and the sole shareholder of its bank, the Rockland Trust Company. Rockland is a community-oriented commercial bank. The bank provides a variety of banking, investment and financial services, operating with various retail branches, as well as a network of commercial and residential lending centers and investment management offices majorly in Eastern Massachusetts, Worcester County, and Rhode Island. The bank's loan portfolio constitutes the bulk of the bank's total assets. Its borrowers consist mostly of small to medium-size businesses and consumers, majority of which are made to its market area in eastern Massachusetts and Rhode Island. The bank's loan portfolio is predominantly in commercial loans.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.